How to read a peptide study (without getting fooled)
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Social media posts love citing PubMed links as "proof." Here is how to tell the difference between rigorous clinical evidence and marketing hype.
1. Human trials vs. animal studies
Over 90% of drugs that show dramatic therapeutic benefits in rodents fail when tested in human clinical trials. Rodents have different enzyme pathways, different receptor densities, and significantly shorter lifespans.
- Animal research is exploratory: It is designed to test mechanisms and preliminary safety, not to determine human dosing or clinical efficacy.
- The BPC-157 example: BPC-157 has dozens of published rat tendon and gut healing papers, yet after 30 years, there is still zero randomized controlled trial evidence in humans.
2. Randomized controlled trials vs. anecdotal reports
The design of a human study determines how much confidence you can place in its conclusions:
| Design | What it means | Level of trust |
|---|---|---|
| Randomized Double-Blind Placebo-Controlled Trial (RCT) | Patients are randomly assigned to drug or inactive placebo; neither patients nor researchers know who took what. Controls for the placebo effect and researcher bias. | Highest |
| Open-Label Trial | Everyone receives the active drug and knows it. Cannot distinguish true pharmacological effects from psychological placebo responses or natural recovery over time. | Moderate |
| Retrospective Chart Review | Doctors review old patient files after the fact. No control group, high selection bias, and impossible to prove cause and effect. | Low |
| Case Report / Anecdote | A report of one or two individuals. Cannot rule out coincidence, other supplements, or natural healing. | Lowest |
3. Sample size: who and how many were tested?
A study of 10 people cannot detect rare side effects and is easily skewed by random chance. Compare these real examples from the site:
- SURMOUNT-1 (Tirzepatide): 2,539 adults followed for 72 weeks across dozens of medical centers with rigorous placebo controls. Statistical confidence is exceptionally high.
- BPC-157 IV Safety Pilot: 2 adults tested over 3 days at a single private clinic. It is impossible to conclude a compound is "safe for human use" from two people over a weekend.
4. Surrogate markers vs. clinical health outcomes
A surrogate marker is a lab number that researchers measure because it is easy to test quickly. A clinical outcome is how a patient actually feels, functions, or survives.
For example, secretagogues like CJC-1295 and Ipamorelin reliably cause a temporary spike in growth hormone (a surrogate marker). But zero clinical studies have demonstrated that this pulse results in increased athletic performance, fat loss, or prolonged lifespan (clinical outcomes). Never assume that raising a blood marker translates to real-world benefit.
5. Sponsor disclosure and funding bias
Always scroll to the end of a paper and check the Conflict of Interest and Funding sections:
- Originator-funded trials: When a drug manufacturer funds a trial of their own molecule (e.g., Lilly funding SURMOUNT-5 or Novo Nordisk funding STEP 1), they design the protocol, control the data analysis, and select the comparator doses. While these trials follow FDA standards, independent replication adds vital credibility.
- Supplement and clinic funding: Watch for studies funded by compounding pharmacies, peptide retailers, or anti-aging clinics with a direct financial incentive to market the compound.
How Cited Peptides grades evidence
We assign every peptide one of four evidence tiers based on the highest level of published research that exists:
| Grade | What it requires | Real example |
|---|---|---|
| FDA-approved | Approved by the FDA (or equivalent major regulator) after rigorous Phase 3 clinical trials demonstrating efficacy and safety. | Semaglutide, Tirzepatide, Tesamorelin, PT-141 |
| Human trials | Controlled clinical trials in living human subjects, but not yet approved as a prescription drug. | Retatrutide, CJC-1295, Ipamorelin |
| Animal studies only | Published research in living animals (rats, mice, rabbits) or tiny uncontrolled human pilots. | BPC-157, TB-500, MOTS-c, AOD-9604 |
| Lab / cell studies only | Test-tube and cell-culture experiments only. No whole-organism animal or human proof. | Isolated in-vitro receptor binding assays |
Common questions
Why do so many animal peptide studies fail to work in humans?
Rats and mice have dramatically faster metabolic rates, distinct immune responses, and different peptide receptor distributions. In lab experiments, animals receive surgically uniform injuries and precisely controlled diets. In human biology, oral or systemic peptides often fail to reach target tissues in active concentrations or produce unexpected toxicities.
What is the difference between a surrogate marker and a clinical outcome?
A surrogate marker is an intermediate biological measurement, like a temporary spike in growth hormone or IGF-1. A clinical outcome is what patients actually care about: gained muscle mass, fewer bone fractures, or reduced heart attacks. Many drugs raise surrogate markers without improving health outcomes.
How does funding bias influence published study results?
Trials funded by pharmaceutical manufacturers are significantly more likely to report favorable outcomes than independent academic trials. When reading a trial, check who paid for the research and whether the investigators had financial ties to the manufacturer.